Smith & Nephew SN.L
Smith & Nephew is a global medical technology company that develops and markets products and technologies in orthopedics, wound management, and surgical technology. Smith & Nephew shows an attractive valuation (forward P/E 11.23, FCF yield 9.40%) and a solid moat (gross margin 68.44%), but growth is modest (revenue +4.60%) and momentum is very weak (12-1: -21.51%), reflecting market doubts about its execution in robotics and competition.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Smith & Nephew is a global medical technology company that develops and markets products and technologies in orthopedics, wound management, and surgical technology. Smith & Nephew shows an attractive valuation (forward P/E 11.23, FCF yield 9.40%) and a solid moat (gross margin 68.44%), but growth is modest (revenue +4.60%) and momentum is very weak (12-1: -21.51%), reflecting market doubts about its execution in robotics and competition.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.6 |
| Quality / Moat | 6.7 |
| Valuation | 7.3 |
| Growth | 5.5 |
| Dividend | 4.7 |
| Momentum | 2.1 |
| Risk & Context | 7.6 |
OVERALL SCORE: 6.3/10
Context and risks
Moderate regulatory risk in the UK due to scrutiny on medical device pricing and the post-Brexit environment. No material exposure to rates, oil, or geopolitics: the medical technology business is defensive and its net debt/EBITDA of 2.19 is not sensitive to a rise in rates.
News considered in the analysis
- S.N. Nuclearelectrica (BVB:SNN) Stock Gets Fair Value Boost As Analysts Rework Growth Assumptions — Titular confuso que mezcla dos empresas distintas (Smith & Nephew y Nuclearelectrica); sin información nueva relevante para SN.L.
- Zimmer proposes to cut 580 jobs in Switzerland — Noticia sobre un competidor (Zimmer Biomet); sin impacto directo en los fundamentales de Smith & Nephew.
- Baxter hires CFO from Smith & Nephew — Pérdida de un directivo clave (CFO) que se marcha a un competidor; impacto moderado en liderazgo financiero, ya parcialmente descontado.
- SNN Advances Surgical Robotics Through Imperial College Partnership — Colaboración académica para avanzar en robótica quirúrgica; refuerza la innovación a largo plazo, aunque el impacto en beneficios es incierto.
- FTSE 100 Live: Blue-chips open higher as miners gain, UK inflation ticks up — Ruido de mercado general sin información específica sobre Smith & Nephew.
Verdict: Hold: reasonable valuation and defensive moat, but wait for signs of growth acceleration or momentum improvement before adding.
Main risk: The main risk is execution in surgical robotics and competition from Zimmer and Stryker, which could limit revenue growth and keep momentum negative.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →